News
Pfizer, Arvinas join SERD club with Veppanu approval
Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.
News
FDA's ODAC delivers one loss, one win for AstraZeneca
The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.
News
AZ will invest £300m in UK, says PM Keir Starmer
AstraZeneca has delivered a much-needed boost to the UK government alongside a strong set of first-quarter results.
News
Amgen, AZ will pilot FDA's real-time clinical trial plan
The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.
News
UK study finds clue to rising cancer rates in younger people
A study has found evidence that 11 cancers are becoming more common among young people in England, and points to a main driving factor.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
